ArticleMolecular pharmacology2021
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Severe acute respiratory syndrome coronavirus 2-mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection.Pharmaceutics · 2025Review
- Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- Molnupiravir: Mechanism of action, clinical, and translational science.Clinical and translational science · 2024Review
- Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.Toxicology research · 2024Article
- Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.Communications medicine · 2023Article
- An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.Reproductive toxicology (Elmsford, N.Y.) · 2023Article
- Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development.Clinical pharmacology and therapeutics · 2023Review
- Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.Fundamental & clinical pharmacology · 2023Review
- Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.International journal of molecular sciences · 2023Article
- Drug Transporters at the Human Blood-Testis Barrier.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
- Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine.ACS omega · 2023Article
- Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.Trends in pharmacological sciences · 2022Review
- The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.Drug metabolism and disposition: the biological fate of chemicals · 2022Article
- Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (International journal of molecular sciences · 2022Review
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.Archives of toxicology · 2022Article
- PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.Clinical and translational science · 2022Article
- Article
- Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites".Molecular pharmacology · 2022Article
- Molnupiravir: A new candidate for COVID-19 treatment.Pharmacology research & perspectives · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Siennah R MillerCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.).
Meghan E McGrathCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.).
Kimberley M ZornCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.).
Sean EkinsCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.).
Stephen H WrightCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.).
Nathan J CherringtonCollege of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., M.E.M., N.J.C.) and Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (K.M.Z., S.E.) cherrington@pharmacy.arizona.edu.
Collaborations Pharmaceuticals (United States) · USUniversity of Arizona · US
Funding
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7MTraining in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7MCentralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3MCircumventing the Blood-Testis BarrierR01GM123643 · NIGMS · UNIVERSITY OF ARIZONA · PI CHERRINGTON, NATHAN J · 2017 to 2020
$1.2MMegaTrans – human transporter machine learning modelsR41GM131433 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, WRIGHT, STEPHEN H · 2019 to 2019
$211kNIEHS NIH HHS P30 ES006694NIEHS NIH HHS T32 ES007091NIGMS NIH HHS R01 GM123643NIGMS NIH HHS R41 GM131433NIGMS NIH HHS R44 GM122196
Abstract
Equilibrative nucleoside transporters (ENTs) are present at the blood-testis barrier (BTB), where they can facilitate antiviral drug disposition to eliminate a sanctuary site for viruses detectable in semen. The purpose of this study was to investigate ENT-drug interactions with three nucleoside analogs, remdesivir, molnupiravir, and molnupiravir's active metabolite,
Indexed as
Adenosine MonophosphateAlanineAntiviral AgentsCOVID-19COVID-19 Drug TreatmentCytidineDose-Response Relationship, DrugDrug InteractionsEquilibrative Nucleoside Transporter 1Equilibrative-Nucleoside Transporter 2HeLa CellsHumansProtein BindingSARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsCytidineEquilibrative Nucleoside Transporter 1Equilibrative-Nucleoside Transporter 2N(4)-hydroxycytidineremdesivirSLC29A1 protein, humanSLC29A2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.